 |
市場調査レポート
商品コード
1069115
ループス治療薬の世界市場：疾患タイプ別、治療タイプ別、投与経路別（経口、皮下、静脈内、その他）、エンドユーザー別、地域別－規模、シェア、展望、機会分析（2022年～2030年）Lupus Therapeutic Market, by Disease Type, by Treatment Type, by Route of Administration (Oral, Subcutaneous, Intravenous, and Others, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
価格
| ループス治療薬の世界市場：疾患タイプ別、治療タイプ別、投与経路別（経口、皮下、静脈内、その他）、エンドユーザー別、地域別－規模、シェア、展望、機会分析（2022年～2030年） |
|
出版日: 2022年03月07日
発行: Coherent Market Insights
ページ情報: 英文 167 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
概要
ループス治療のための新規治療薬の開発に向けた急速な研究開発活動、市場で活躍する主要企業による買収や提携などの無機的成長戦略の採用の増加が、市場の成長を促進すると予想されます。
当レポートでは、世界のループス治療薬市場について調査しており、市場展望、市場力学、市場分析、競合情勢など、包括的な情報を提供しています。
目次
第1章 調査目的・前提条件
第2章 市場の展望
- レポートの説明
- 市場の定義と範囲
- エグゼクティブサマリー
- 市場の内訳：疾患タイプ別
- 市場の内訳：治療タイプ別
- 市場の内訳：投与経路別
- 市場の内訳：エンドユーザー別
- 市場の内訳：地域別
- コヒーレントオポチュニティマップ（COM）
第3章 市場力学、規制、および動向分析
- 市場力学
- 促進要因
- 抑制要因
- 市場機会
- 治療オプション分析
- 代替/代替情勢
- 治療の安全性と有効性の分析
- 治療アルゴリズム（ペイシェントジャーニー）
- 医薬品承認の実績ロードマップ
- 活動部位（作用機序）
- 薬剤耐性シナリオ
- 償還シナリオ
- 治療費
- ブランドマッピング
- パイプライン分析
- 疫学
- 最近の製品承認
- 規制シナリオ
- 健康技術評価
- PEST分析
- 合併、買収、コラボレーションのシナリオ
- 米国での遵守率
- 米国でのスイッチ分析
- 特許満了シナリオ
- 疾病啓発プログラム
- 製品回収
- リスクと悪影響
第4章 世界のループス治療薬市場－コロナウイルス（COVID-19）パンデミックの影響
- 経済的影響
- 臨床試験と医薬品開発への影響
- 政府のイニシアチブ
第5章 世界のループス治療薬市場：疾患タイプ別（100万米ドル）（2017年～2030年）
- イントロダクション
- 全身性エリテマトーデス
- 皮膚ループスエリテマトーデス
- 薬剤誘発性ループスエリテマトーデス
- 新生児エリテマトーデス
第6章 世界のループス治療薬市場：治療タイプ別（100万米ドル）（2017年～2030年）
- イントロダクション
- 非ステロイド性抗炎症薬
- 生物製剤
- 抗マラリア薬
- コルチコステロイド
- その他（疾患修飾性抗リウマチ薬、抗凝固薬など）
第7章 世界のループス治療薬市場：投与経路別（100万米ドル）（2017年～2030年）
- イントロダクション
- 経口
- 皮下
- 静脈内
- その他（筋肉内、皮内など）
第8章 世界のループス治療薬市場：エンドユーザー別（100万米ドル）（2017年～2030年）
- イントロダクション
- 病院とクリニック
- 診断ラボ
- その他（在宅医療、専門センターなど）
第9章 世界のループス治療薬市場：地域別（100万米ドル）（2017年～2030年）
- イントロダクション
- 北米
- ラテンアメリカ
- 欧州
- アジア太平洋
- 中東
- アフリカ
第10章 競合情勢
- ヒートマップ分析
- 市場シェア分析
- Hikma Pharmaceuticals PLC
- Lupus Therapeutics
- Dr. Reddy's Laboratories Ltd.
- GlaxoSmithKline plc
- Amgen Inc.
- Novartis AG
- Sanofi
- UCB SA
- ImmuPharma PLC
- Bayer AG
- Merck &Co., Inc.
- Aurinia Pharmaceuticals Inc.
- Pfizer Inc.
- ADMA Biologics, Inc.
- AstraZeneca
- F.Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International Gmbh
- アナリストの見解
第11章 セクション
目次
Product Code: CMI4958
Lupus is an autoimmune disorder wherein the immune system of the body attacks body's own healthy tissues and organs, resulting in swelling, tissue damage, and pain. The inflammation caused by lupus can affect the joints, kidneys, brain, blood cells, skin, heart, and lungs. The exact cause of lupus is unknown, however, certain risk factors are associated with lupus. These risk factors include hormones, genetics, smoking, viral infection, and others. Some of the common symptoms related to lupus include fatigue, muscle and joint pain, fever, mouth ulcers, headaches, arthritis, malar rash, unusual hair loss, and others. Diagnosis of lupus is difficult as its symptoms mimic those of other ailments such as rheumatoid arthritis, scleroderma, etc. However, a butterfly-shaped rash, also known as malar rash across the nose and cheek is a highly distinctive feature of lupus. There are other complications that can arise from lupus, such as urinary tract infections, yeast infections, herpes, pregnancy loss, bone tissue death, and others.
Market Dynamics
The high prevalence and incidence of lupus, rapid research and development activities towards development of novel therapeutics for treatment of lupus, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global lupus therapeutic market over the forecast period.
For instance, according to an article published by the Lupus Science and Medicine journal, in April 2021, it is estimated that the incidence and prevalence of Systemic Lupus Erythematosus (SLE) were around 0.3 to 5.1 per 100 000 per year and 6.5 to 85 per 100 000 population, respectively in Europe in 2020.
Key features of the study:
- This report provides an in-depth analysis of the global lupus therapeutic market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global lupus therapeutic market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global lupus therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lupus therapeutic market
Detailed Segmentation:
- Global Lupus Therapeutic Market, By Disease Type:
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus
- Drug-Induced Lupus Erythematosus
- Neonatal Lupus
- Global Lupus Therapeutic Market, By Treatment Type:
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Biologics
- Antimalarial Drugs
- Corticosteroids
- Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
- Global Lupus Therapeutic Market, By Route Of Administration:
- Oral
- Subcutaneous
- Intravenous
- Others (Intramuscular, Intradermal, among others)
- Global Lupus Therapeutic Market, By End User:
- Hospitals & Clinics
- Diagnostic Laboratories
- Others (Homecare, Specialty Centre, among others)
- Global Lupus Therapeutic Market, By Region:
- North America
- By Disease Type
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus
- Drug-Induced Lupus Erythematosus
- Neonatal Lupus
- By Treatment Type
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Biologics
- Antimalarial Drugs
- Corticosteroids
- Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
- By Route Of Administration
- Oral
- Subcutaneous
- Intravenous
- Others (Intramuscular, Intradermal, among others)
- By End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Others (Homecare, Specialty Centre, among others)
- By Country
- U.S.
- Canada
- Latin America
- By Disease Type
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus
- Drug-Induced Lupus Erythematosus
- Neonatal Lupus
- By Treatment Type
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Biologics
- Antimalarial Drugs
- Corticosteroids
- Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
- By Route Of Administration
- Oral
- Subcutaneous
- Intravenous
- Others (Intramuscular, Intradermal, among others)
- By End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Others (Homecare, Specialty Centre, among others)
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Disease Type
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus
- Drug-Induced Lupus Erythematosus
- Neonatal Lupus
- By Treatment Type
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Biologics
- Antimalarial Drugs
- Corticosteroids
- Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
- By Route Of Administration
- Oral
- Subcutaneous
- Intravenous
- Others (Intramuscular, Intradermal, among others)
- By End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Others (Homecare, Specialty Centre, among others)
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Disease Type
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus
- Drug-Induced Lupus Erythematosus
- Neonatal Lupus
- By Treatment Type
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Biologics
- Antimalarial Drugs
- Corticosteroids
- Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
- By Route Of Administration
- Oral
- Subcutaneous
- Intravenous
- Others (Intramuscular, Intradermal, among others)
- By End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Others (Homecare, Specialty Centre, among others)
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Disease Type
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus
- Drug-Induced Lupus Erythematosus
- Neonatal Lupus
- By Treatment Type
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Biologics
- Antimalarial Drugs
- Corticosteroids
- Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
- By Route Of Administration
- Oral
- Subcutaneous
- Intravenous
- Others (Intramuscular, Intradermal, among others)
- By End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Others (Homecare, Specialty Centre, among others)
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Disease Type
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus
- Drug-Induced Lupus Erythematosus
- Neonatal Lupus
- By Treatment Type
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Biologics
- Antimalarial Drugs
- Corticosteroids
- Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
- By Route Of Administration
- Oral
- Subcutaneous
- Intravenous
- Others (Intramuscular, Intradermal, among others)
- By End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Others (Homecare, Specialty Centre, among others)
- By Country/Region
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- Hikma Pharmaceuticals PLC*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Lupus Therapeutics
- Dr. Reddy's Laboratories Ltd.
- GlaxoSmithKline plc
- Amgen Inc.
- Novartis AG
- Sanofi
- UCB S.A.
- ImmuPharma PLC
- Bayer AG
- Merck & Co., Inc.
- Aurinia Pharmaceuticals Inc.
- Pfizer Inc.
- ADMA Biologics, Inc.
- AstraZeneca
- F.Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International Gmbh
- Hikma Pharmaceuticals PLC*
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Treatment Type
- Market Snippet, By Route of Administration
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Treatment Option Analysis
- Alternate/Substitute Landscape
- Treatment Safety and Efficacy Analysis
- Treatment Algorithm (Patient Journey)
- Historical Roadmap of Drug Approvals
- Site of Activity (Mode of Action)
- Drug Resistance Scenario
- Reimbursement Scenario
- Cost of therapy
- Brand Mapping
- Pipeline Analysis
- Epidemiology
- Recent Product Approvals
- Regulatory Scenario
- Health-Technology Assessment
- PEST Analysis
- Mergers, Acquisitions and Collaboration Scenario
- Adherence rate in U.S.
- Switch analysis in U.S.
- Patent Expiry Scenario
- Disease Awareness Programs
- Product Recall
- Risk and Adverse effects
4. Global Lupus Therapeutic Market - Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- Impact on Clinical Trials and Drug Development
- Government Initiatives
5. Global Lupus Therapeutic Market, By Disease Type, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
- Systemic Lupus Erythematosus (SLE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Cutaneous Lupus Erythematosus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Drug-Induced Lupus Erythematosus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Neonatal Lupus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
6. Global Lupus Therapeutic Market, By Treatment Type, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Antimalarial Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
7. Global Lupus Therapeutic Market, By Route of Administration, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Others (Intramuscular, Intradermal, among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
8. Global Lupus Therapeutic Market, By End User, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
- Hospitals & Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Others (Homecare, Specialty Centre, among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
9. Global Lupus Therapeutic Market, By Region, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
- North America
- Market Size and Forecast, By Disease Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Disease Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Disease Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Disease Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Disease Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Disease Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
- South Africa
- Central Africa
- North Africa
10. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Hikma Pharmaceuticals PLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Lupus Therapeutics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amgen Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- UCB S.A.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- ImmuPharma PLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Aurinia Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- ADMA Biologics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AstraZeneca
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- F.Hoffmann-La Roche Ltd
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Boehringer Ingelheim International Gmbh
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
11. Section
- References
- Research Methodology
- About us and Sales Contact
